



SITUATION REPORT

Nigeria Centre for Disease Control and Prevention

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov   

TITLE:	UPDATE ON MPOX (MPX) IN NIGERIA
SERIAL NUMBER:	4
EPI-WEEK:	4
DATE:	January 29, 2023

Table 1 – Key Indicators

Reporting year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 4	52	3	0	0.0	2	3
2023 Cumulative	Week 4	186	27	1	3.7	12 + FCT	22
2022 Cumulative	Week 4	7	0	0	0.0	0	0

Highlights

- In week 4, the number of new suspected cases is 52, compared with 79 cases reported in week 3, 2023. These were reported from eighteen (18) states and FCT – Lagos (16), Nasarawa (6), Plateau (5), Ogun (4), Anambra (3), Edo (2), FCT (2), Imo (2), Kaduna (2), Abia (1), Enugu (1), Katsina (1), Kebbi (1), Kwara (1), Ondo (1), Oyo (1), Rivers (1), Taraba (1) and Zamfara (1) across 32 Local Government Areas. Since week 1 of 2023, twelve (12) states and FCT have recorded at least one confirmed Mpox case across twenty-two (22) Local Government Areas.
- Since the beginning of 2023, the States with the highest burden are Lagos (22.2%), Abia (14.8%), Imo (14.8%), FCT (11.1%) and Borno (7.4%), contributing 70.3% of confirmed cases.
- The number of confirmed cases is three (3) in week 4, 2023, compared with eleven (11) confirmed cases reported in week 3, 2023.
- No death was recorded in week 4, with a CFR of 0.0% same as CFR of 0.0% that was reported in week 3, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 2821 suspected cases have been reported from 36 states and FCT in the country. Of these 2821 suspected cases, 1015 (35.9%) were confirmed (with males predominantly affected) from 34 states and FCT. Sixteen (16) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.






Figure 1: Epidemic curve of suspected and confirmed Mpox cases January 2023 till date




Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date





Figure 3: Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date

Figure 4 Area chart for States showing the trend in suspected and confirmed Mpox cases in highest burden States from January 2023 till date






Figure 5: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 29nd January 2023

Table 1: Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 29th January 2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	186	27	1	3.7	12 + FCT	22
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

Table 2: Age distribution of cumulative number of confirmed Mpox cases September 2017 – 29th January 2023

Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	4	143
11-20 Years	12	4	1	0	4	123	2	146
21-30 Years	34	13	13	4	10	187	8	269
31- 40 Years	26	17	22	4	13	205	6	293
41-50 Years	9	10	9	0	5	89	5	127
> 50 Years	0	0	1	0	1	33	2	37
Total	88	49	47	8	34	762	27	1015

Table 3: Nigeria Confirmed Mpox cases by State, September 2017 – 29th January 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	6	224
2	Rivers	25	14	7	1	5	37	0	89
3	Bayelsa	19	11	7	0	6	45	1	89
4	Abia	1	2	0	0	0	58	4	65
5	Delta	3	6	10	1	9	31	0	60
6	Imo	5	2	1	0	0	45	4	57
7	Ogun	0	0	0	0	1	40	1	42
8	Ondo	0	0	0	0	0	40	0	40
9	Edo	4	1	1	0	4	27	1	38
10	FCT	5	0	0	0	1	25	3	34
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	0	26
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	1	20
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Oyo	1	3	2	0	0	10	0	16
19	Kaduna	0	0	0	0	0	15	1	16
20	Ebonyi	0	0	0	1	0	12	0	13
21	Benue	2	0	0	0	0	10	0	12
22	Borno	0	0	0	0	0	11	2	13
23	Enugu	1	2	1	0	0	4	1	9
24	Katsina	0	0	0	0	0	8	0	8
25	Taraba	0	0	0	0	0	7	0	7
26	Kano	0	0	0	0	0	7	0	7
27	Gombe	0	0	0	0	0	6	0	6
28	Kogi	0	0	0	0	0	5	1	6
29	Osun	0	0	0	0	0	5	0	5
30	Ekiti	2	0	0	0	0	1	0	3
31	Niger	0	0	0	0	1	1	0	2
32	Kebbi	0	0	0	0	0	2	0	2
33	Bauchi	0	0	0	0	0	1	0	1
34	Zamfara	0	0	0	0	0	1	0	1
35	Yobe	0	0	0	0	0	1	0	1
	Grand Total	88	49	47	8	34	762	27	1015

Response activities

Pillar	Activities to date	Next steps
Coordination	<ul style="list-style-type: none"> Held a meeting with FAO to kickstart eleven (11) activities to improve surveillance, testing and response to Mpox in the animal sector 	<ul style="list-style-type: none"> Follow-up with states to obtain challenges and provide feedback to the Mpox TWG Commence Mpox response activities in the animal health sector
Surveillance	<ul style="list-style-type: none"> No death reported in current week Incomplete entry of key variables in case investigation form (Sex, age and date of symptoms onset) from reporting states (Lagos, Nasarawa, Plateau, Enugu and Imo state) 	<ul style="list-style-type: none"> Engage Lagos, Nasarawa, Plateau, Enugu and Imo states on updating the case investigation forms
Laboratory	<ul style="list-style-type: none"> Current sample positivity rate for Mpox is 6% and 83% for Varicella-zoster virus (VZV) Conducted retrospective HIV testing for 915 Mpox samples from 2022: 6.5% positivity for HIV only and 5% positivity for Mpox and HIV co-infection 79% of samples met overall turnaround (time sample collected from states to time result shared to states) 	<ul style="list-style-type: none"> Test all the remaining samples for in 2022 and 2023 for HIV infection
IPC	<ul style="list-style-type: none"> Trained four (4) HCWs and 20 resource persons amongst IHVN staff as part of National Training of Trainers for Hand Hygiene audit and multimodal hand hygiene improvement strategy held 	<ul style="list-style-type: none"> Continue printing of isolation precaution signages for healthcare facilities
Risk communication	<ul style="list-style-type: none"> Analysed 987 Mpox related conversations on social media platforms: message saturation, mistrust in data, and disbelief in the disease were the three main themes that emerged 	<ul style="list-style-type: none"> Plan for a National Perception Survey Engage states on strategies to mitigate infodemics detected Update and disseminate public health advisory addressing identified misinformation
Research	<ul style="list-style-type: none"> Nigeria has the highest number of confirmed Mpox cases and the 4th highest case fatality ratio (0.9%) In Italy, Mpox virus DNA was detected in wastewater from the largest Italian airport in Rome using real-time PCR assays 	<ul style="list-style-type: none"> Plan to commence wastewater surveillance -as one of the approaches to Mpox detection and prevention

Notes on this report

Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

Case definitions

Suspected case

- An acute illness with fever $>38.3^{\circ}\text{C}$, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand

Probable case

- A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case

Confirmed case

- A clinically compatible case that is laboratory confirmed

Contact

- Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

Calculations

- Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.